Hyperandrogenemia is implicated in both the metabolic and reproductive morbidities of polycystic ovary syndrome
- PMID: 24424368
- DOI: 10.1016/j.fertnstert.2013.11.027
Hyperandrogenemia is implicated in both the metabolic and reproductive morbidities of polycystic ovary syndrome
Abstract
Objective: To determine the features of polycystic ovary syndrome (PCOS) that are implicated in the associated reproductive and metabolic morbidities.
Design: Cross-sectional case-control study.
Setting: Academic medical setting.
Patient(s): A total of 1,062 women with PCOS and 1,887 women without PCOS.
Intervention(s): None.
Main outcome measure(s): Physical examination including hirsutism scoring, biochemical and hormone measurements, ovarian ultrasound, and a 75-g oral glucose tolerance test to measure glucose and insulin levels.
Result(s): A factor analysis identified four dominant factors in women with PCOS. These factors were interpreted as follows: [1] metabolic and hyperandrogenemia factor, [2] oligomenorrhea and hyperandrogenemia factor, [3] blood pressure factor, and [4] ovarian morphology factor. In women with PCOS, hyperandrogenemia was a significant predictor of metabolic syndrome after adjusting for age, body mass index, and insulin resistance in the regression analysis.
Conclusion(s): A factor analysis identified multiple factors that are responsible for the abnormalities associated with PCOS. Hyperandrogenemia was a common underlying feature of the metabolic and reproductive abnormalities in women with PCOS but not in women without PCOS.
Keywords: Hyperandrogenemia; metabolic morbidity; polycystic ovary syndrome; reproductive morbidity.
Copyright © 2014 American Society for Reproductive Medicine. Published by Elsevier Inc. All rights reserved.
Similar articles
-
Cross-sectional analysis of the effects of age on the hormonal, metabolic, and ultrasonographic features and the prevalence of the different phenotypes of polycystic ovary syndrome.Fertil Steril. 2012 Feb;97(2):494-500. doi: 10.1016/j.fertnstert.2011.11.041. Epub 2011 Dec 21. Fertil Steril. 2012. PMID: 22192350
-
Normo- and hyperandrogenic women with polycystic ovary syndrome exhibit an adverse metabolic profile through life.Fertil Steril. 2017 Mar;107(3):788-795.e2. doi: 10.1016/j.fertnstert.2016.12.017. Epub 2017 Jan 12. Fertil Steril. 2017. PMID: 28089571
-
Dietary glycemic index is associated with less favorable anthropometric and metabolic profiles in polycystic ovary syndrome women with different phenotypes.Fertil Steril. 2013 Oct;100(4):1081-8. doi: 10.1016/j.fertnstert.2013.06.005. Epub 2013 Jul 2. Fertil Steril. 2013. PMID: 23830153
-
Polycystic ovary syndrome: a common but often unrecognized condition.J Midwifery Womens Health. 2012 May-Jun;57(3):221-30. doi: 10.1111/j.1542-2011.2012.00161.x. J Midwifery Womens Health. 2012. PMID: 22594862 Review.
-
Polycystic ovarian syndrome: the commonest cause of hyperandrogenemia in women as a risk factor for metabolic syndrome.Minerva Endocrinol. 2007 Mar;32(1):35-47. Minerva Endocrinol. 2007. PMID: 17353865 Review.
Cited by
-
Polycystic ovary syndrome: aggressive or protective factor for the retina? Evaluation of macular thickness and retinal nerve fiber layers using high-definition optical coherence tomography.J Ophthalmol. 2015;2015:193078. doi: 10.1155/2015/193078. Epub 2015 Feb 11. J Ophthalmol. 2015. PMID: 25763280 Free PMC article.
-
The PCOS GWAS Candidate Gene ZNF217 Influences Theca Cell Expression of DENND1A.V2, CYP17A1, and Androgen Production.J Endocr Soc. 2022 May 13;6(7):bvac078. doi: 10.1210/jendso/bvac078. eCollection 2022 Jul 1. J Endocr Soc. 2022. PMID: 35668995 Free PMC article.
-
Sonographic markers of ovarian morphology, but not hirsutism indices, predict serum total testosterone in women with regular menstrual cycles.Fertil Steril. 2016 May;105(5):1322-1329.e1. doi: 10.1016/j.fertnstert.2015.12.136. Epub 2016 Jan 27. Fertil Steril. 2016. PMID: 26794423 Free PMC article.
-
miRNA Profiling Reveals miRNA-130b-3p Mediates DENND1A Variant 2 Expression and Androgen Biosynthesis.Endocrinology. 2019 Aug 1;160(8):1964-1981. doi: 10.1210/en.2019-00013. Endocrinology. 2019. PMID: 31184707 Free PMC article.
-
CTBP1‑AS upregulation is associated with polycystic ovary syndrome and can be effectively downregulated by cryptotanshinone.Mol Med Rep. 2022 Jul;26(1):245. doi: 10.3892/mmr.2022.12761. Epub 2022 Jun 3. Mol Med Rep. 2022. PMID: 35656892 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical